| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Ademetionine (AdoMet; SAMe; MSI-195; S-adenosylmethionine) is a common co-substrate involving in the transfer of methyl group to biological molecules such as nucleic acids, proteins and lipids. It can be potentially used for treatment of primary biliary cirrhosis and major depressive disorder.
| ln Vitro |
In Cal-33 and JHU-SCC-011 cells, S-adenosyl-L-methionine (300 µM, 24 or 48 hours) activates cells and encourages cell cycle marketing [4]. S-adenosyl-L-methionine (300 S-adenosyl-L-methionine (5–40 μg/mL, 48 h) inhibits Cal–33 and JHU-SCC-011 cell migration while protecting 5‑FU migration by controlling DNMT expression (μM, 24 h) [4]. Analysis of apoptosis [4]
|
|---|---|
| ln Vivo |
S-adenosyl-L-methionine (30 mg/kg, facial, for 3 days) prevents ASD-like behaviors caused by valproic acid exposure in early postnatal rats [6]. S-adenosyl-L-methionine (50 and 100)
|
| Cell Assay |
Apoptosis analysis [4]
Cell Types: Cal-33 and JHU-SCC-011 cells Tested Concentrations: 300 μM Incubation Duration: 24 hrs (hours) (Cal-33) or 48 hrs (hours) ( HU-SCC-011) results. Anti-cancer effect [5]. Experimental Results: demonstrated approximately 10% and 3% of apoptotic cells respectively. Cell cycle analysis [4] Cell Types: Cal-33 and JHU-SCC-011 Cell Tested Concentrations: 300 µM Incubation Duration: 24 hrs (hours) (Cal-33) or 48 hrs (hours) (HU-SCC-011) Experimental Results: Cyclin expression diminished B1, E1, and D1 in Cal-33 and JHU-SCC-011 cells. |
| Animal Protocol |
Animal/Disease Models: Valproic acid-treated young rats [6]
Doses: 30 mg/kg Route of Administration: Oral for 3 days Experimental Results: Remission of most autism spectrum disorders (ASD)-like neurobehavioral symptoms. Normalizes redox potential in the prefrontal cortex. |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
S-Adenosylmethionine is absorbed from the small intestine following oral intake. As absorption is affected by food, it is best to take on an empty stomach. Bioavailability is low following oral intake. Metabolism / Metabolites Significant first-pass metabolism in the liver. Approximately 50% of S-Adenosylmethionine (SAMe) is metabolized in the liver. SAMe is metabolized to S-adenosylhomocysteine, which is then metabolized to homocysteine. Homocysteine can either be metabolized to cystathionine and then cysteine or to methionine. The cofactor in the metabolism of homocysteine to cysteine is vitamin B6. Cofactors for the metabolism of homocysteine to methionine are folic acid, vitamin B12 and betaine. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation SAM-e (S-adenosylmethionine) is a naturally occurring methyl radical donor involved in enzymatic transmethylation reactions in humans and animals. SAM-e has no specific lactation-related uses, but it has been used therapeutically for treating postpartum depression, cholestatic jaundice, osteoarthritis and numerous other conditions. SAM-e has poor oral bioavailability. SAM-e is generally well tolerated in adults. The most frequent adverse effects reported are gastrointestinal, such as nausea. Skin rashes have also been reported. No information is available on the clinical use of SAM-e during breastfeeding. However, use of SAM-e by a nursing mother would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months. Dietary supplements do not require extensive pre-marketing approval from the U.S. Food and Drug Administration. Manufacturers are responsible to ensure the safety, but do not need to prove the safety and effectiveness of dietary supplements before they are marketed. Dietary supplements may contain multiple ingredients, and differences are often found between labeled and actual ingredients or their amounts. A manufacturer may contract with an independent organization to verify the quality of a product or its ingredients, but that does not certify the safety or effectiveness of a product. Because of the above issues, clinical testing results on one product may not be applicable to other products. More detailed information about dietary supplements is available elsewhere on the LactMed Web site. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. |
| References | |
| Additional Infomation |
S-adenosyl-L-methioninate is a sulfonium betaine that is a conjugate base of S-adenosyl-L-methionine obtained by the deprotonation of the carboxy group. It has a role as a human metabolite. It is functionally related to a L-methioninate. It is a conjugate base of a S-adenosyl-L-methionine.
Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed) S-Adenosylmethionine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). S-adenosylmethionine has been reported in Homo sapiens and Pisum sativum with data available. S-Adenosylmethionine is a nutritional supplement that is synthesized from adenosine triphosphate (ATP) and the amino acid methionine by the endogenous essential enzyme methionine adenosyltransferase (MAT), with potential antineoplastic activity. Upon administration, S-adenosylmethionine acts as a methyl donor for various transmethylation reactions. In cancer cells, this agent induces the methylation of tumor promoting genes, reverses DNA hypomethylation, and leads to the suppression of oncogene transcription. This induces apoptosis in and inhibits proliferation of susceptible tumor cells. Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed) See also: S-Adenosyl-L-methionine Disulfate Tosylate (active moiety of); S-Adenosylmethionine chloride (is active moiety of). Drug Indication S-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being. Mechanism of Action S-Adenosylmethionine (SAMe) is a natural substance present in the cells of the body. It is a direct metabolite of the essential amino acid L-methionine. SAMe plays a crucial biochemical role in the body by donating a one-carbon methyl group in a process called transmethylation. SAMe, formed from the reaction of L-methionine and adenosine triphosphate catalyzed by the enzyme S-adenosylmethionine synthetase, is the methyl-group donor in the biosynthesis of both DNA and RNA nucleic acids, phospholipids, proteins, epinephrine, melatonin, creatine and other molecules. Pharmacodynamics S-adenosylmethionine is an intermediate metabolite of methionine. Its involvement in methylation assists in cellular growth and repair, maintains the phospho-bilipid layer in cell membranes. It also helps in the maintenance of the action of several hormones and neurotransmitters that affect mood. Highest concentration are found in the brain and the liver. |
| Molecular Formula |
C15H22N6O5S
|
|---|---|
| Molecular Weight |
398.438
|
| Exact Mass |
398.137
|
| CAS # |
29908-03-0
|
| Related CAS # |
S-Adenosyl-L-methionine tosylate;52248-03-0;S-Adenosyl-L-methionine-d3;68684-40-2;S-Adenosyl-L-methionine disulfate tosylate;97540-22-2;S-Adenosyl-L-methionine iodide;3493-13-8;S-Adenosyl-L-methionine (1,4-butanedisulfonate);200393-05-1;S-Adenosyl-L-methionine-13C;74084-24-5
|
| PubChem CID |
34755
|
| Appearance |
Off-white to light yellow solid powder
|
| Melting Point |
247-249ºC
|
| LogP |
-2.8
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
527
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
|
| InChi Key |
MEFKEPWMEQBLKI-AIRLBKTGSA-N
|
| InChi Code |
InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1
|
| Chemical Name |
(2S)-2-amino-4-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(methyl)sulfonio)butanoate
|
| Synonyms |
S-adenosylmethionineMSI195AdoMet MSI-195 SAMeMSI 195 AdemetionineHeptral Gumbaral.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~250.98 mM)
H2O : ≥ 43 mg/mL (~107.92 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5098 mL | 12.5489 mL | 25.0979 mL | |
| 5 mM | 0.5020 mL | 2.5098 mL | 5.0196 mL | |
| 10 mM | 0.2510 mL | 1.2549 mL | 2.5098 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06026865 | Recruiting | Dietary Supplement: S-Adenosyl-L- methionine (SAMe) |
Primary Sclerosing Cholangitis (PSC) | Medical University of Warsaw | August 1, 2023 | Not Applicable |
| NCT02200029 | Completed | Drug: Ademetionine IV+tablet Drug: Ademetionine tablet |
Intrahepatic Cholestasis Associated With Alcoholic Liver Disease |
Abbott | June 2014 | Phase 3 |
| NCT04623034 | Completed | Drug: Ademetionine | Major Depressive Disorder | MSI Methylation Sciences, Inc. | April 17, 2013 | Phase 1 |
| NCT02557360 | Completed | Dietary Supplement: S-adenosyl-L- methionine |
Primary Biliary Cirrhosis | Pomeranian Medical University Szczecin | November 2015 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
